银屑病是一种免疫介导的皮肤炎症性疾病,其特征在于角质形成细胞的不受控制的增殖和功能失调的分化。在我们的案例系列中,吡非尼酮用于治疗纤维化肺病,偶然,我们注意到在治疗开始几个月后,共存的皮肤银屑病病变缓解。吡非尼酮的抗纤维化和免疫调节特性已得到充分研究,没有完全阐明。与此相符,吡非尼酮可能在其他免疫介导的疾病如牛皮癣中发挥多效性治疗作用,while,同时,避免目前抗银屑病药物的免疫抑制相关副作用。吡非尼酮介导的皮肤角质形成细胞对紫外线A和紫外线B的吸收增强可能是一种潜在的机制。吡非尼酮作为抗银屑病药物的可能作用需要大规模和长期的研究。
Psoriasis is an immune-mediated inflammatory disorder of the skin, characterised by uncontrolled proliferation and dysfunctional differentiation of keratinocytes. In our case series, pirfenidone was administered for the management of fibrotic lung disease and, serendipitously, we noticed remission of coexisting cutaneous psoriatic lesions few months after treatment initiation. Pirfenidone\'s antifibrotic and immunomodulatory properties have been well studied; yet, not fully elucidated. In line with this, pirfenidone may exert pleiotropic therapeutic effects in other immune-mediated diseases such as psoriasis, while, at the same time, spare immunosuppression-related side effects of current antipsoriatic drugs. Pirfenidone-mediated enhanced absorption of ultraviolet A and ultraviolet B by skin keratinocytes might represent a potential mechanism. The possible role of pirfenidone as an antipsoriatic drug requires large-scale and long-term study.